Harnessing the immune system to beat cancer
why
High unmet medical need
Many cancer patients do not benefit from current immunotherapies, such as immune checkpoint inhibitors*.
Up to 80% of the patients do not benefit from immuno checkpoint inhibitors*
*Chen, S. et al. "Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials." Front. Oncol. 11:562315 (2021).
How
Our technology
Ayuvant is developing a novel immunotherapy based on RNA-nanoparticles that instruct the immune system on how to recognise and attack cancer cells.
Our science
Unique features
Non-inflammatory RNA nanoparticle platform targeting the immune system
Specific immunotherapy inducing long-term memory effects
Strong antitumor activity in immune checkpoint inhibitors-resistant models
Team
Who we are
.JPG)
Our Partners and Supporters
News
Stay updated
July 17, 2024
Gert Storm receives two prestigious career awards.
Ayuvant's Co-funder and CSO receives two lifetime career awards in Glasgow and Bologna
May 17, 2024
Why is Ayuvant's mission so important?
Co-funder and CEO Lucas Czentner reflects on Ayuvant's and his own personal mission
May 13, 2024
Can scientists make it as CEOs?
Do not miss Lucas's thoughts and impressions on this topic!
May 20, 2024
Ayuvant at the Dutch consulate in San Francisco
Ayuvant had the honour to be present in Dutch consulate in SF
July 10, 2023
From PhD research to cancer treatment: Lucas Czentner does it all
By starting a company, PhD candidate Lucas Czentner makes great strides
December 15, 2023
Exciting News! The Academic Startup Competition proudly unveils the top 20 finalists!
These visionary companies are set to make a significant impact across
